Viral Vitalism

Source Library

FDA approves Wegovy for metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis

U.S. Food and Drug Administration is tracked in the Viral Vitalism canonical source library.

GovernmentU.S. health regulator
Source type
Government
Access type
Official
Publisher
U.S. Food and Drug Administration
Date
2025-08-15
Added
2026-06-19
Open original ->Source index

Trust profile

94

U.S. health regulator

Publisher type
Regulator
Bias profile
Low

Best used for

  • Approvals
  • Labels
  • Safety communications

Weak for

  • Comparative effectiveness
  • Consumer experience

Used in Viral Vitalism

Claims supported

  • Semaglutide has phase 3 MASH evidence and regulatory relevance for a defined noncirrhotic population with fibrosis.

Related studies

ESSENCEPhase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis

Related sources

Topic tags

glp-1semaglutidewegovymashliver-healthmetabolic-health

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No miracle claims. Just better health signal.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.